Your browser doesn't support javascript.
loading
Welding PROxAb Shuttles: A Modular Approach for Generating Bispecific Antibodies via Site-Specific Protein-Protein Conjugation.
Lehmann, Tanja; Schneider, Hendrik; Tonillo, Jason; Schanz, Jennifer; Schwarz, Daniel; Schröter, Christian; Jäger, Sebastian; Kolmar, Harald; Hecht, Stefan; Anderl, Jan; Rasche, Nicolas; Rieker, Marcel; Dickgiesser, Stephan.
Afiliação
  • Lehmann T; Clemens-Schöpf-Institut für Organische Chemie und Biochemie, Technische Universität Darmstadt, 64287 Darmstadt, Germany.
  • Schneider H; ADCs & Targeted NBE Therapeutics, Merck KGaA, 64293 Darmstadt , Germany.
  • Tonillo J; ADCs & Targeted NBE Therapeutics, Merck KGaA, 64293 Darmstadt , Germany.
  • Schanz J; ADCs & Targeted NBE Therapeutics, Merck KGaA, 64293 Darmstadt , Germany.
  • Schwarz D; ADCs & Targeted NBE Therapeutics, Merck KGaA, 64293 Darmstadt , Germany.
  • Schröter C; Discovery Pharmacology, Merck KGaA, 64293 Darmstadt, Germany.
  • Jäger S; ADCs & Targeted NBE Therapeutics, Merck KGaA, 64293 Darmstadt , Germany.
  • Kolmar H; ADCs & Targeted NBE Therapeutics, Merck KGaA, 64293 Darmstadt , Germany.
  • Hecht S; Clemens-Schöpf-Institut für Organische Chemie und Biochemie, Technische Universität Darmstadt, 64287 Darmstadt, Germany.
  • Anderl J; ADCs & Targeted NBE Therapeutics, Merck KGaA, 64293 Darmstadt , Germany.
  • Rasche N; ADCs & Targeted NBE Therapeutics, Merck KGaA, 64293 Darmstadt , Germany.
  • Rieker M; ADCs & Targeted NBE Therapeutics, Merck KGaA, 64293 Darmstadt , Germany.
  • Dickgiesser S; ADCs & Targeted NBE Therapeutics, Merck KGaA, 64293 Darmstadt , Germany.
Bioconjug Chem ; 35(6): 780-789, 2024 Jun 19.
Article em En | MEDLINE | ID: mdl-38809610
ABSTRACT
Targeted protein degradation is an innovative therapeutic strategy to selectively eliminate disease-causing proteins. Exemplified by proteolysis-targeting chimeras (PROTACs), they have shown promise in overcoming drug resistance and targeting previously undruggable proteins. However, PROTACs face challenges, such as low oral bioavailability and limited selectivity. The recently published PROxAb Shuttle technology offers a solution enabling the targeted delivery of PROTACs using antibodies fused with PROTAC-binding domains derived from camelid single-domain antibodies (VHHs). Here, a modular approach to quickly generate PROxAb Shuttles by enzymatically coupling PROTAC-binding VHHs to off-the-shelf antibodies was developed. The resulting conjugates retained their target binding and internalization properties, and incubation with BRD4-targeting PROTACs resulted in formation of defined PROxAb-PROTAC complexes. These complexes selectively induced degradation of the BRD4 protein, resulting in cytotoxicity specifically to cells expressing the antibody's target. The chemoenzymatic approach described herein provides a versatile and efficient solution for generating antibody-VHH conjugates for targeted protein degradation applications, but it could also be used to combine antibodies and VHH binders to generate bispecific antibodies for further applications.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Anticorpos Biespecíficos / Proteólise Limite: Humans Idioma: En Revista: Bioconjug Chem Assunto da revista: BIOQUIMICA Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Alemanha

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Anticorpos Biespecíficos / Proteólise Limite: Humans Idioma: En Revista: Bioconjug Chem Assunto da revista: BIOQUIMICA Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Alemanha